BioMarin Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
BioMarin Pharmaceutical has a total shareholder equity of $4.9B and total debt of $1.1B, which brings its debt-to-equity ratio to 22.2%. Its total assets and total liabilities are $6.8B and $1.9B respectively. BioMarin Pharmaceutical's EBIT is $120.0M making its interest coverage ratio -3.5. It has cash and short-term investments of $1.1B.
Key information
22.2%
Debt to equity ratio
US$1.09b
Debt
Interest coverage ratio | -3.5x |
Cash | US$1.13b |
Equity | US$4.90b |
Total liabilities | US$1.86b |
Total assets | US$6.76b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BM8's short term assets ($3.0B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: BM8's short term assets ($3.0B) exceed its long term liabilities ($698.0M).
Debt to Equity History and Analysis
Debt Level: BM8 has more cash than its total debt.
Reducing Debt: BM8's debt to equity ratio has reduced from 41.2% to 22.2% over the past 5 years.
Debt Coverage: BM8's debt is not well covered by operating cash flow (12.8%).
Interest Coverage: BM8 earns more interest than it pays, so coverage of interest payments is not a concern.